Corr, B., Thomas, S., Haight, P., Stock, E., Floyd, J., Borden, L., … Gaillard, S. (2023). PR023/#503  Evaluation of the combination lenvatinib and pembrolizumab in endometrial cancer; a real world multi-institutional review of practice patterns, efficacy and tolerability. In International Journal of Gynecological Cancer (Vol. 33, pp. A43–A44). Elsevier BV. https://doi.org/10.1136/ijgc-2023-igcs.65

Corr, Bradley, Samantha Thomas, Paulina Haight, Elizabeth Stock, Jessica Floyd, Lindsay Borden, Irina Tunnage, et al. “PR023/#503  Evaluation of the combination lenvatinib and pembrolizumab in endometrial cancer; a real world multi-institutional review of practice patterns, efficacy and tolerability.” In International Journal of Gynecological Cancer, 33:A43–44. Elsevier BV, 2023. https://doi.org/10.1136/ijgc-2023-igcs.65.

Corr B, Thomas S, Haight P, Stock E, Floyd J, Borden L, et al. PR023/#503  Evaluation of the combination lenvatinib and pembrolizumab in endometrial cancer; a real world multi-institutional review of practice patterns, efficacy and tolerability. In: International Journal of Gynecological Cancer. Elsevier BV; 2023. p. A43–4.

Corr, Bradley, et al. “PR023/#503  Evaluation of the combination lenvatinib and pembrolizumab in endometrial cancer; a real world multi-institutional review of practice patterns, efficacy and tolerability.” International Journal of Gynecological Cancer, vol. 33, Elsevier BV, 2023, pp. A43–44. Crossref, doi:10.1136/ijgc-2023-igcs.65.

Corr B, Thomas S, Haight P, Stock E, Floyd J, Borden L, Tunnage I, Secord AA, Arend R, Jackson A, Wright J, Konecny G, Castellano T, Ko E, Podwika S, Backes F, Spinosa D, Mullen M, Washington C, Pothuri B, Smitherman C, Harsono A, Khadraoui H, Suzuki Y, Salani R, Powell K, Subbarao S, Gaillard S. PR023/#503  Evaluation of the combination lenvatinib and pembrolizumab in endometrial cancer; a real world multi-institutional review of practice patterns, efficacy and tolerability. International Journal of Gynecological Cancer. Elsevier BV; 2023. p. A43–A44.